Change and disruption continue to cloud the European pharmaceutical landscape led, unsurprisingly, by Brexit.
The summer saw confirmation of what a jewel in the crown the EMA really is, with 19 of the EU’s soon-to-be 27 member states officially throwing their hats into the ring for the competition to host the regulator.
That decision is due to be made in November. Before that there’s much planning to be done, and we look at some of the Brexit options and outcomes for pharma.
Our September issue then takes a wider view of the European political landscape, digging in to the electoral implications of this year’s ballots in Germany, France and the UK.
Sticking with change, but taking a welcome break from Brexit, this month’s PME also takes aim at increasing the effectiveness of strategic planning and how to successfully enact business change.
Finally, we hear from Mylan’s European president Jacek Glinka about the company’s growth strategy, and LEO Pharma’s VP for Europe North Geraldine Murphy talks to us about trial transparency.
View PME September 2017 online
Register here to receive email notification of future digital editions of PME or contact the subscriptions department to enquire about receiving a print copy of the magazine. More PMLiVE digital editions can be found here.
PME is also available to download as an app for iPhone and iPad
